首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Ccl21c |
| Uniprot No | P86793 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-133aa |
| 氨基酸序列 | SDGGGQDCCLKYSQKKIPYSIVRGYRKQEPSLGCPIPAILFLPRKHSKPELCANPEEGWVQNLMRRLDQPPAPGKQSPGCRKNRGTSKSGKKGKGSKGCKRTEQTQPSRG |
| 预测分子量 | 12.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL21c(或CCL21)重组蛋白的3-4条参考文献示例(文献信息为模拟概括，建议通过学术数据库核实原文)：
---
1. **文献名称**: *"Recombinant CCL21 induces dendritic cell migration and antitumor immunity in vivo"*
**作者**: Matsumura S, et al.
**摘要**: 研究通过大肠杆菌表达重组CCL21蛋白，验证其体外趋化树突状细胞的能力，并证明其在小鼠模型中通过募集免疫细胞增强抗肿瘤反应。
2. **文献名称**: *"CCL21-mediated recruitment of T cells to tumors enhances checkpoint inhibitor efficacy"*
**作者**: Sharma S, et al.
**摘要**: 利用重组CCL21蛋白局部注射肿瘤模型，观察到T细胞浸润显著增加，联合PD-1抑制剂可协同抑制肿瘤生长，提示其在免疫治疗中的潜在应用。
3. **文献名称**: *"Expression and functional characterization of recombinant murine CCL21 in lymphoid development"*
**作者**: Lu J, et al.
**摘要**: 在哺乳动物细胞系统中表达重组CCL21.分析其在小鼠淋巴组织发育中的作用，发现其通过结合CXCR3受体调控淋巴细胞归巢。
4. **文献名称**: *"Purification and bioactivity analysis of CCL21c variant from yeast expression system"*
**作者**: Sánchez M, et al.
**摘要**: 描述在毕赤酵母中高效表达并纯化重组CCL21c蛋白，通过体外趋化实验和受体结合实验证实其生物活性，为后续药物开发提供基础。
---
**注意**：以上文献信息为模拟生成，实际引用时请通过PubMed、Google Scholar等平台核对原文准确性。
Ccl21c, a splice variant of the CCL21 chemokine, belongs to the CC chemokine family and plays a critical role in immune cell trafficking and lymphoid tissue organization. The full-length CCL21 gene produces multiple isoforms (Ccl21a, Ccl21b, Ccl21c) through alternative splicing, with Ccl21c distinguished by its unique C-terminal sequence. This protein is primarily secreted by stromal cells in lymph nodes and high endothelial venules, where it binds to the CCR7 receptor on dendritic cells, T cells, and B cells, guiding their migration to secondary lymphoid organs. Unlike other isoforms, Ccl21c lacks a heparin-binding domain, altering its tissue distribution and functional interactions.
Recombinant Ccl21c is produced using expression systems like E. coli or mammalian cells, followed by purification via affinity tags (e.g., His-tag) and chromatography. Quality validation typically involves SDS-PAGE, Western blotting, and functional assays to confirm receptor-binding activity. Its production enables controlled studies on CCR7-mediated signaling, lymphocyte homing, and immune responses in vitro and in vivo.
Research applications include investigating immune cell recruitment in inflammation, cancer metastasis (where CCR7-CCL21 axes often promote tumor dissemination), and lymphoid neogenesis. Ccl21c is also explored as a therapeutic target or adjuvant to modulate immune activity in autoimmune diseases or vaccine development. However, functional differences between Ccl21 isoforms and species-specific variations (human vs. murine models) require careful interpretation. Current studies focus on resolving its structural nuances and tissue-specific roles to harness its potential in immunotherapy and diagnostic strategies.
×
